Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. Issue 3 (April 2019)

• Record Type: Journal Article
• Authors: Sharma, Mukul; Hart, Robert G; Smith, Eric E; Bosch, Jackie; Yuan, Fei; Casanova, Amparo; Eikelboom, John W; Connolly, Stuart J; Wong, Gloria; Diaz, Rafael; Lopez-Jaramillo, Patricio; Ertl, Georg; Störk, Stefan; Dagenais, Gilles R; Lonn, Eva M; Ryden, Lars; Tonkin, Andrew M; Varigos, John D; Bhatt, Deepak L; Branch, Kelley RH; Probstfield, Jeffrey L; Kim, Jae-Hyung; Ha, Jong-Won; O'Donnell, Martin; Vinereanu, Dragos; Fox, Keith AA; Liang, Yan; Liu, Lisheng; Zhu, Jun; Pogosova, Nana; Maggioni, Aldo P; Avezum, Alvaro; Piegas, Leopoldo S; Keltai, Katalin; Keltai, Matyas; Cook Bruns, Nancy; Berkowitz, Scott; Yusuf, Salim;
• Is Part Of: International journal of stroke. Volume 14:Issue 3(2019)
• Page Start: 270
• Page End: 281
• Publication Date: 2019-04
• Subjects: Magnetic resonance imaging -- silent infarct -- cognition -- prevention -- anticoagulant -- clinical trial; 616.8005
• DOI: 10.1177/1747493018784478
• Languages: English
• ISSNs: 1747-4930

Abstract

Background: Covert vascular disease of the brain manifests as infarcts, white matter hyperintensities, and microbleeds on MRI. Their cumulative effect is often a decline in cognition, motor impairment, and psychiatric disorders. Preventive therapies for covert brain ischemia have not been established but represent a huge unmet clinical need. Aims: The MRI substudy examines the effects of the antithrombotic regimens in COMPASS on incident covert brain infarcts (the primary outcome), white matter hyperintensities, and cognitive and functional status in a sample of consenting COMPASS participants without contraindications to MRI. Methods: COMPASS is a randomized superiority trial testing rivaroxaban 2.5 mg bid plus acetylsalicylic acid 100 mg and rivaroxaban 5 mg bid against acetylsalicylic acid 100 mg per day for the combined endpoint of MI, stroke, and cardiovascular death in individuals with stable coronary artery disease or peripheral artery disease. T1-weighted, T2-weighted, T2*-weighted, and FLAIR images were obtained close to randomization and near the termination of assigned antithrombotic therapy; biomarker and genetic samples at randomization and one month, and cognitive and functional assessment at randomization, after two years and at the end of study. Results: Between March 2013 and May 2016, 1905 participants were recruited from 86 centers in 16 countries. Of these participants, 1760 underwent baseline MRI scans that were deemed technically adequate for interpretation. The mean age at entry of participants with interpretable MRI was 71 years and 23.5% were women. Coronary artery disease was present in 90.4% and 28.1% had peripheral artery disease. Brain infarcts were present in 34.8%, 29.3% had cerebral microbleeds, and 93.0% had white matter hyperintensities. The median Montreal Cognitive Assessment score was 26 (interquartile range 23–28). Conclusions: The COMPASS MRI substudy will examine the effect of the antithrombotic interventions on MRI-determined covert brain infarcts and cognition. Demonstration of a therapeutic effect of the antithrombotic regimens on brain infarcts would have implications for prevention of cognitive decline and provide insight into the pathogenesis of vascular cognitive decline.